SynAIRgy
106 evidence topics · 17 sources
Objective
Trial objective as stated in the publication
“To evaluate the efficacy/safety of AD109 over 6 months in a diverse OSA population unable to use PAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted the phase 3 SynAIRgy clinical trial to evaluate the efficacy, safety, and tolerability of AD109 vs placebo over 6 months in adults with mild-to-severe OSA who were intolerant to or refused PAP therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary objectives in the design paper
“The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary objectives are to demonstrate efficacy of AD109 vs placebo on OSA symptoms including fatigue, one of the most common and bothersome OSA symptoms [[13], [14], [15]], and on measures of oxygenation which have been shown to correlate more strongly than AHI with adverse cardiovascular outcomes [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory objectives for both trials involve in-depth examination of the effects of AD109 on sleep parameters, and additional measures of airway obstruction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Sites and countries
“conducted at 69 sites in the United States and Canada” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, trial sites were limited to the United States and Canada and may not fully represent OSA in other geographies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of centers, May to October 2025, superseded in May 2026
Registry study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2023-09-16” |
| Primary completion (actual) | “2025-03-10” |
| Study completion (actual) | “2025-03-14” |
| Enrollment (actual) | “646” |
Registry results posting dates
| Field | Quoted record |
|---|---|
| Results first submitted | “2026-08-18” |
| Results first posted | “2026-09-11” |
Study design
Randomized, double-blind, placebo-controlled parallel-arm design
“SynAIRgy (APC-APN-305; NCT05813275)35 was a phase 3, randomized, double-blind, placebo-controlled, 6-month parallel-arm study of AD109 (Figure S1), conducted at 69 sites in the United States and Canada in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines outlined by the International Council for Harmonisation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible participants were randomized 1:1 to receive AD109 or placebo and stratified according to baseline AHI (<15, 15 to <30, ≥30 events/hour) and PROMIS-Fatigue T-score (<58.5 vs ≥58.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design record
| Field | Quoted record |
|---|---|
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
Visit schedule and polysomnography timing
“Participants received AD109 or placebo during a 26-week period, including a 1-week run-in dose followed by 25 weeks at the target dose, then 2 weeks without dosing, followed by last visit at week 28 (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standard overnight polysomnography (PSG) was performed at baseline and weeks 4 and 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key patient-reported outcomes (PROs) were assessed using PROMIS-Fatigue and PROMIS-Sleep Impairment 8-item questionnaires at baseline and weeks 4, 13, and 26 (Supplementary Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity strata enrollment limits
“To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding, central polysomnography scoring, and data monitoring
“All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Separate sites from the LunAIRo trial
“LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory cohort of GLP-1 receptor agonist users not analyzed
“An additional exploratory cohort of up to 100 participants receiving a concomitant glucagon-like peptide-1 (GLP-1) receptor agonist specifically for weight loss (ie, not for treatment of type 2 diabetes) was initiated and planned to be analyzed separately to evaluate the potential impact of weight loss on the efficacy and safety of AD109 compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to low enrollment in this cohort, the prespecified exploratory analyses are not included in this report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optional open-label extension after completion
Planned randomization and in-treatment polysomnography in the design abstract
Eligibility criteria
Inclusion and exclusion criteria in the publication
“Patients aged ≥18 years with mild-to-severe OSA who had failed or refused PAP therapy were screened for eligibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with AHI ≥5 events/hour were initially enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An apnea was defined by an event with ≥90% reduction in airflow for ≥10 seconds and hypopnea by ≥30% reduction in airflow for ≥10 seconds associated with a ≥4% decrease in the oxygen saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The eligibility criterion of enrolling participants with AHI ≥5 events/hour was subsequently changed to ≥10 to ≤45 events/hour to avoid overrepresentation of participants with very severe or very mild OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other inclusion criteria were an 8-item Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue T-score >50, representing above-average fatigue and a body mass index (BMI) of 18.5 to 40 kg/m2 in men or 18.5 to 42 kg/m2 in women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria were clinically significant or medically uncontrolled cardiovascular disease, presence of narcolepsy, restless leg syndrome requiring medication, rapid eye movement (REM) sleep behavior disorder, bothersome symptoms of insomnia, and craniofacial malformation syndromes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry inclusion criteria, current version
Apnea-hypopnea index eligibility range in protocol amendment 5.0, February 2024
Registry exclusion criteria
Definitions of PAP failure and PAP refusal
“PAP failure is defined as no PAP use for ≥3 months prior to randomization, or return/removal of PAP device from the home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAP refusal is defined as refusal of PAP after prior positive sleep study, or prior refusal of provider-recommended sleep study due to unwillingness to consider PAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue threshold expressed as raw score and T-score
Additional exclusion criteria in the design paper
“Clinically significant or medically uncontrolled cardiovascular disease, or resting heart rate >100), untreated or unstable coronary artery disease, heart failure, cerebrovascular event or revascularization within 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disallowed concomitant medications
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Modafinil, armodafinil, solriamfetol, and pitolisant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral anticholinergics, and cholinesterase inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs used exclusively for weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apnea-hypopnea index eligibility in protocol versions 2.0 and 4.0, July 2023, superseded in February 2024
Apnea-hypopnea index eligibility in congress abstracts, April 2024 and May 2025, superseded in May 2026
Treatment
AD109 regimen with one-week run-in and no dose reduction
Registry intervention descriptions
Dispensing and dosing rules
“The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Run-in dose in base notation and reason dose reduction was not permitted
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: change in AHI with 4% desaturation hypopnea rule at week 26
Key secondary and exploratory endpoints
“The key secondary efficacy endpoints (at week 26) were change from baseline in oxygen desaturation index based on 3% desaturation (ODI), PROMIS-Fatigue T-score, hypoxic burden based on 4% desaturation (HB), PROMIS-Sleep Impairment T-score, and proportion of participants with ≥50% reduction in AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prespecified exploratory endpoints (at week 26) included change from baseline in OSA severity category (none [AHI <5], mild [AHI 5 to <15], moderate [AHI 15 to <30], and severe [AHI ≥30]), proportion of participants with AHI reduction of ≥30% to ≥90% by 10% increments, and proportion of breaths with snoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other secondary endpoints in the design paper
“Other secondary endpoints in both trials include the change from baseline in the PGI-S score for fatigue at Week 26, the patient global impression of change (PGI-C) score for fatigue at Week 26, and the change from baseline in ESS at Week 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for AHI, oxygen desaturation index, and hypoxic burden
“The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease [[22], [23], [24], [25]].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for PROMIS-Fatigue as a key secondary endpoint
“Fatigue is one of the most common and most bothersome symptoms of OSA and is a distinct symptom from sleepiness [13].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Content validity and meaningful change of the patient-reported outcome measures, SynAIRgy exit interviews
“Qualitative exit interviews were conducted with 32 participants within 10 days of completing the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mapping demonstrated all PROMs have strong concept coverage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants reported a one-point change on response options for individual items from the PROMIS-Fatigue (61%-96%), PROMIS-Sleep Impairment (52%-96%), and ESS (62-96%) was clinically meaningful, regardless of baseline response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A one-point change on PROMs represents a clinically meaningful improvement from the patient's perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Investigators' rationale for the clinical meaningfulness of the AHI change, treatment policy and on-treatment estimands
“At the group level, treatment was associated with a shift in disease severity from the moderate to mild range (from a median of 19.8 at baseline to 13.3 at week 26 in the ITT, and from a median of 19.3 at baseline to 10.6 at week 26 in the on-treatment estimand).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This magnitude of improvement, we believe, is clinically meaningful, as mild OSA has been associated with lower cardiovascular, metabolic, and neurocognitive risk compared to moderate OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 26 weeks, >25% of participants in the AD109 arm achieved ≥50% reduction in AHI, a clinically meaningful improvement based on American Academy of Sleep Medicine guidelines,45,46 although this effect was not statistically significant compared with the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company position on relative rather than absolute AHI change in mild and moderate disease
FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results
Editorial comment on the clinical significance of the absolute AHI change, treatment policy estimand
Protocol amendment 6.0 reordering the primary and key secondary endpoints, April 2025
Primary endpoint: responder proportion in protocol version 4.0, December 2023, superseded in April 2025
Primary endpoint: responder proportion in the registry record, March 2025, superseded in November 2025
Primary endpoint: responder proportion in congress abstracts, April 2024 and May 2025, superseded in May 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“The sample size (640 participants) was calculated based on the number of participants required to provide >90% power for the primary endpoint and one of the key secondary efficacy endpoints (change from baseline to week 26 in PROMIS-Fatigue T-score) at a 2-sided significance level of 0.05 (Supplementary Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size assumptions from the MARIPOSA trial
“In a previous Phase 2 study (MARIPOSA), the standard deviation of the placebo group change from baseline in AHI4 was approximately 9.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed
Participants excluded from the efficacy analyses
“The 7 participants (5 in the AD109 arm and 2 in the placebo arm) randomized and treated in the exploratory cohort are included in the safety analysis but not in the efficacy analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen participants enrolled at site 1416 in the AD106 arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six participants enrolled at site 1416 in the placebo arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These numbers reflect participants by assigned treatment, but 2 participants who were assigned to placebo received AD109 instead.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Treatment policy estimand (intent-to-treat) and on-treatment estimand
“Primary analyses of the efficacy endpoints were performed using an intent-to-treat approach (ITT); supportive analyses were performed using the on-treatment estimand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ITT analysis included all randomized participants who received ≥1 dose of AD109/placebo and evaluated endpoints regardless of treatment adherence or discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the ITT estimand, missing data were assumed to be missing-not-at-random, and endpoints were analyzed with a pattern-mixture model using a jump-to-reference approach by means of sequential modeling with multiple imputation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The on-treatment estimand included all randomized participants who received ≥1 dose of AD109/placebo and who had ≥1 post-baseline PSG assessment on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The on-treatment estimand focused on endpoints observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last observation carried forward approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry definitions of the Primary Full Analysis Set and While-on-Treatment population
Statistical model and responder analysis
“The primary analysis for the primary and secondary endpoints defined on a continuous scale used a restricted maximum likelihood–based mixed model for repeated measurements in combination with the Newton–Raphson algorithm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of the proportion of participants with ≥50% reduction in AHI at week 26 (key secondary endpoint not on a continuous scale) was conducted using the stratified Cochran–Mantel–Haenszel procedure, and estimates of risk difference between arms, along with the 2-sided 95% CI, were calculated based on the Cochran–Mantel–Haenszel stratum weights38 and the Sato variance estimator.39” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the proportion of participants with ≥50% reduction in AHI, participants who discontinued treatment were considered nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control and hierarchical testing order
“For the primary endpoint, no adjustment for multiplicity was needed and a 2-sided 5% significance level was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjustment for multiplicity of the key secondary endpoints was conducted through a closed testing approach, where each key secondary endpoint was tested in a prespecified order: (1) change from baseline to week 26 in ODI, (2) change from baseline to week 26 in PROMIS-Fatigue T-score, (3) change from baseline to week 26 in HB, (4) change from baseline to week 26 in PROMIS-Sleep Impairment T-score, and (5) proportion of participants with ≥50% reduction in AHI at week 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key secondary endpoints that are nominally statistically significant but occur after a nonsignificant result in the prespecified hierarchical testing sequence should be interpreted with caution, as formal statistical significance cannot be claimed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative change in AHI on the log scale added as an exploratory analysis in statistical analysis plan version 2.0, April 2025
Per-protocol population as described by the company
Results
Participant disposition
Trial completion and completion of six months of treatment
“Among participants who received treatment, 84.6% (539/637) completed the trial, with 83.3% (265/318) in the AD109 group and 85.9% (274/319) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 74.7% (476/637) completed 6 months of treatment (65.7% [209/318] with AD109 and 83.7% [267/319] with placebo; Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment adherence
“In the AD109 arm, treatment adherence (percent compliant) was 95.7% (SD, 9.2%) for participants completing the study on treatment, and 90.2% (SD, 35.2%) for those discontinuing treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the placebo arm, treatment adherence was 95.5% (SD, 9.5%) for participants completing the study on treatment, and 77.5% (SD, 42.4%) for those discontinuing treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall treatment discontinuation before week 26
Timing of treatment discontinuation
“AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, non-AE-related discontinuations were similar between the AD109 and placebo arms and were distributed more uniformly over time and generally at lower counts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry participant flow and reasons for study withdrawal
Main cohort completion in the congress abstract
Baseline characteristics
Baseline characteristics, intent-to-treat set, AHI with 4% desaturation hypopnea rule
Distribution of baseline severity and body mass index in the intent-to-treat set
“The distribution of baseline OSA severity was broad and right-skewed with 34.8% (214/615) mild, 42.1% (259/615) moderate, and 23.1% (142/615) severe (Table 1, Figure S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline insomnia was assessed based on participant-reported medical history obtained at screening and includes initial insomnia (difficulty falling asleep at the beginning of the night), insomnia, and middle insomnia (difficulty maintaining sleep, characterized by frequent or prolonged nighttime awakenings).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry baseline age and mean AHI with 4% desaturation hypopnea rule, Primary Full Analysis Set
| Characteristic | AD109 | Placebo | Total |
|---|---|---|---|
| Age, years, mean (SD) | “57.5(10.67)” | “57.1(11.11)” | “57.3(10.89)” |
| Baseline AHI4, events/hr, mean (SD) | “22.13(11.819)” | “21.47(10.607)” | “21.79(11.214)” |
Baseline characteristics, all 646 randomized participants, AHI with 4% desaturation hypopnea rule
Baseline oxygenation measures, all 646 randomized participants
| Characteristic | Quoted value |
|---|---|
| ODI3, mean (SD) | “29 (13)”View highlighted excerpt for this quote |
| HB4, mean (SD) | “43 (40)”View highlighted excerpt for this quote |
Efficacy results
Primary and key secondary endpoints at week 26, treatment policy estimand, AHI with 4% desaturation hypopnea rule
Relative reduction in AHI with 4% desaturation hypopnea rule at week 26, treatment policy estimand
“These changes represent a model-estimated 44.1% geometric mean reduction in AHI from baseline to week 26 in the AD109 arm vs 17.6% reduction in the placebo arm (P <.0001; Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (95% CI) AHI was reduced from 19.8 (18.3-21.2) in the moderate severity range at baseline to 13.3 (10.7-15.9) in the mild severity range at week 26 with AD109, and from 19.1 (17.0-20.2) at baseline to 17.7 (15.3-20.8) at week 26 with placebo (Figure 2B; Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 placebo-adjusted AHI change and responder difference, treatment policy estimand
“The placebo-adjusted reduction at week 4 was −5.7 (−7.5 to −3.8); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment difference at week 4 was 21.7 (14.8-28.5); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary endpoint result for change in AHI with 4% desaturation hypopnea rule at 6 months, treatment policy and while-on-treatment estimands
Primary and key secondary endpoints at week 26, on-treatment estimand, AHI with 4% desaturation hypopnea rule
Relative and median AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand
Week 4 placebo-adjusted AHI change and responder difference, on-treatment estimand
“The placebo-adjusted reduction at week 4 was −6.7 (−8.7 to −4.8); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment difference at week 4 was 27.1 (19.7-34.4); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative AHI reduction by estimand as reported by the company
Topline primary endpoint result and relative AHI reduction, as reported in the company release
Responders with at least 50% AHI reduction at weeks 4 and 26, treatment policy and on-treatment estimands
“Clinically meaningful response was observed as early as week 4 based on the ≥50% reduction in AHI responder rates, suggesting that the lower treatment difference at week 26 could be attributed to the higher early treatment discontinuation rate with AD109 relative to placebo, since participants who discontinued treatment were classified as nonresponders in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity category improvement and disease control at week 26, treatment policy estimand
“AD109 improved OSA disease severity category in 41.8% of participants (vs 33.6% for placebo), with 17.6% achieving complete OSA disease control (AHI <5) at week 26 vs 9.3% for placebo (P = .012; Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions ≥70% in AHI at week 26 were reported in 17.2% (52/302) of the AD109 arm vs 8.9% (28/313) in the placebo arm (P = .003; Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity category improvement and disease control at week 26, on-treatment estimand
Oxygen desaturation index with 3% desaturation criterion, relative change by estimand
Oxygen desaturation index and hypoxic burden, on-treatment estimand, as reported in the CHEST 2025 company release
Hypoxic burden with 4% desaturation criterion outside formal hierarchical testing, treatment policy estimand
“Based on the prespecified hierarchical testing approach for secondary endpoints, formal endpoint testing ended before analysis of HB.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The geometric mean percent reduction in HB at week 26 was 44.7% for participants in the AD109 arm vs 8.5% for participants in the placebo arm (nominal P <.0001; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-REM, REM, and supine AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand
Apnea index and hypopnea index at week 26, on-treatment estimand
Arousal indexes at week 26, on-treatment estimand
| Measure | AD109 change, median (IQR) | Placebo change, median (IQR) |
|---|---|---|
| Respiratory arousal index, events/h | “0.1 (−5.0 to 5.8)”View highlighted excerpt for this quote | “1.3 (−3.5 to 7.5)”View highlighted excerpt for this quote |
| Total arousal index, events/h | “2.9 (−2.5 to 10.5)”View highlighted excerpt for this quote | “1.6 (−3.9 to 8.7)”View highlighted excerpt for this quote |
Subgroups and adjustment for REM sleep and body mass index, treatment policy and on-treatment estimands
“Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evaluation of the treatment effect on AHI and HB at week 26 performed with an adjusted model including the change from baseline in proportion of REM sleep and BMI is provided in Table S3 and shows that the reduction in AHI is independent from reduction in REM and BMI in the treatment arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
PROMIS-Fatigue at week 26, treatment policy and on-treatment estimands
“AD109 reduced PROMIS-Fatigue T-scores at week 26 by a mean of 7.4 points compared with 6.2 points in the control arm, such that the difference between arms did not meet statistical significance (P = .059; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the supportive on-treatment estimand analyses, PROMIS-Fatigue T-scores fell at week 26 by 7.5 points with AD109 vs 6.2 points with placebo (P = .030; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue by baseline fatigue and daytime sleepiness, treatment policy estimand
PROMIS-Sleep Impairment at week 26, treatment policy estimand
“The PROMIS-Sleep Impairment T-score improved by 7.6 points in the AD109 arm but the improvement in the placebo arm was similar, such that no treatment effect was observed between arms (P = .316; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue and PROMIS-Sleep Impairment at week 26, on-treatment estimand, congress abstract
Placebo response in patient-reported outcomes
“The substantial improvement in symptoms observed in both arms suggests that the placebo effect may have impaired the ability to detect true clinical improvements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of PRO assessments, participants were never specifically asked if they were aware of receiving placebo, so we cannot rule out the possibility of expectation bias influencing responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Editorial comment on patient-reported outcomes
Epworth Sleepiness Scale and patient global impression endpoints
No evidence found.
Safety results
Overall safety summary, safety analysis set
Treatment discontinuation due to adverse events
“Overall, 21.2% (69/325) of participants receiving AD109 and 3.1% (10/319) of participants receiving placebo discontinued treatment due to an AE (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary (occurring in ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events leading to treatment discontinuation in two or more participants
| Event | AD109 (n = 325), n (%) |
|---|---|
| Insomnia | “16 (4.9)”View highlighted excerpt for this quote |
| Urinary hesitation | “8 (2.5)”View highlighted excerpt for this quote |
| Nausea | “7 (2.2)”View highlighted excerpt for this quote |
| Erectile dysfunction or sexual dysfunction | “5 (1.5)”View highlighted excerpt for this quote |
| Dry mouth | “4 (1.2)”View highlighted excerpt for this quote |
| Hypertension | “3 (0.9)”View highlighted excerpt for this quote |
| Palpitations | “3 (0.9)”View highlighted excerpt for this quote |
| Upper abdominal pain | “2 (0.6)”View highlighted excerpt for this quote |
| Feeling jittery | “2 (0.6)”View highlighted excerpt for this quote |
| Urinary retention | “2 (0.6)”View highlighted excerpt for this quote |
Severity of adverse events and serious adverse events
“The most common AEs were generally mild in severity (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious AEs were reported by 1.5% (5/325) of participants who received AD109 and 2.5% (8/319) of participants who received placebo; all were deemed by investigators to be unrelated to study medication (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AD109 arm, 5 participants experienced the following serious adverse events (all unrelated to AD109 treatment): 1 participant had cholelithiasis and cholestatic hepatitis, 1 participant had gastritis and bacterial pneumonia, 1 participant had asthma and chronic obstructive pulmonary disease, 1 participant had cholecystitis, and 1 participant had malignant melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No deaths were reported in the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events at the 5% reporting threshold, safety population
| Event | AD109, affected/at risk (%) | Placebo, affected/at risk (%) |
|---|---|---|
| Serious adverse events, total | “5/325 (1.54%)” | “8/319 (2.51%)” |
| Other adverse events, total | “176/325 (54.15%)” | “50/319 (15.67%)” |
| Dry mouth | “115/325 (35.38%)” | “29/319 (9.09%)” |
| Nausea | “37/325 (11.38%)” | “2/319 (0.63%)” |
| Constipation | “17/325 (5.23%)” | “4/319 (1.25%)” |
| Somnolence | “17/325 (5.23%)” | “10/319 (3.13%)” |
| Middle insomnia | “38/325 (11.69%)” | “10/319 (3.13%)” |
| Initial insomnia | “30/325 (9.23%)” | “4/319 (1.25%)” |
| Urinary hesitation | “29/325 (8.92%)” | “1/319 (0.31%)” |
Any adverse event counts in the congress abstract
Heart rate and blood pressure, safety analysis set
| Measure | AD109, mean change (SD) [n] | Placebo, mean change (SD) [n] |
|---|---|---|
| Heart rate, beats/min, baseline day 1 to week 26 day 1 | “1.5 (9.8) [268]”View highlighted excerpt for this quote | “−1.9 (10.1) [277]”View highlighted excerpt for this quote |
| Heart rate, beats/min, baseline day 2 to week 26 day 2 | “3.6 (9.4) [267]”View highlighted excerpt for this quote | “0.0 (9.2) [276]”View highlighted excerpt for this quote |
| Systolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “1.4 (11.8) [268]”View highlighted excerpt for this quote | “1.7 (11.9) [277]”View highlighted excerpt for this quote |
| Diastolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “0.9 (8.0) [268]”View highlighted excerpt for this quote | “−0.5 (7.7) [277]”View highlighted excerpt for this quote |
Heart rate of 100 beats per minute or higher at any time on treatment
“Changes in blood pressure and heart rate were small, although a small subgroup of participants showed tachycardia while on AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) | P value |
|---|---|---|---|
| Heart rate ≥100 beats/min, on study | “20 (6.3)”View highlighted excerpt for this quote | “6 (1.9)”View highlighted excerpt for this quote | “.006”View highlighted excerpt for this quote |
| Systolic blood pressure ≥140 mm Hg, on study | “83 (26.3)”View highlighted excerpt for this quote | “82 (26.5)”View highlighted excerpt for this quote | “.939”View highlighted excerpt for this quote |
| Diastolic blood pressure ≥90 mm Hg, on study | “65 (20.6)”View highlighted excerpt for this quote | “64 (20.7)”View highlighted excerpt for this quote | “.956”View highlighted excerpt for this quote |
Sleep architecture at week 26, post hoc analysis in the safety analysis set
Insomnia as a reason for discontinuation and baseline insomnia assessment
“The population studied must have been intolerant to or refused PAP therapy to enroll; thus, the trial may have been enriched with participants who may have exhibited some degree of subclinical insomnia.41 However, insomnia was not assessed in a standardized manner in this trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Editorial comment on tolerability and long-term safety
Study limitations
Summary
- Design: 26 weeks of treatment against placebo, with polysomnography at baseline and weeks 4 and 26; no active comparator. Dose reduction was not permitted, and participants could start PAP during the trial.
- Population: adults intolerant of or refusing PAP, with a PROMIS-Fatigue T-score above 50 and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, bothersome insomnia, specified psychiatric disorders, and narrow angle glaucoma. Sites were limited to the United States and Canada, which the authors state may not represent OSA in other geographies.
- Eligibility AHI changed during enrollment: protocol version 2.0 (July 2023) required more than 5 to 45 events/h, version 5.0 (February 2024) required 10 to 45, and the publication states participants with AHI of 5 or more were enrolled first. The 2024 congress abstract described AHI4 of 5 or more, and the 2025 abstract AHI4 above 5 with no upper limit. Enrollment ran from December 20, 2023 to March 26, 2025.
- Severity mix: enrollment limits capped each AHI4 stratum at about 20% to 40%, and the authors state the population skewed toward mild-to-moderate disease, which can limit absolute effects; the editorial gives a median baseline AHI of 19.6.
- Endpoint change: protocol version 4.0 (December 2023) named the proportion with at least 50% AHI reduction as the primary endpoint. Amendment 6.0 (17 April 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry version of 2025-03-18 named the proportion of participants with reduction in AHI as the primary outcome, and the next version, submitted 2025-11-18, changed the outcome measures. The amendment postdates the registry's actual primary completion date (2025-03-10). Statistical analysis plan version 2.0 (22 April 2025) added the relative change in AHI on the log scale as an exploratory analysis.
- Estimands and missing data: the primary treatment policy analysis assumed data missing not at random (jump-to-reference multiple imputation). The supportive on-treatment estimand excluded data collected after treatment discontinuation and imputed missing values by last observation carried forward; it included 260 participants on AD109 and 296 on placebo, against 302 and 313 in the treatment policy set. The topline release reported the on-treatment relative reduction (55.6%) beside the treatment policy primary result (p=0.001).
- Analysis-set exclusions: 22 participants (16 AD109, 6 placebo) at site 1416, terminated for Good Clinical Practice noncompliance, and 7 participants in the exploratory GLP-1 receptor agonist cohort were excluded from efficacy analyses; that cohort's analyses were not reported because of low enrollment.
- Discontinuation: treatment discontinuation before 26 weeks was 34.3% with AD109 and 16.3% with placebo in the publication, which the authors state likely diminished the observed benefit; the prospectus reports 34.6% and 16.5% at month 6 in the main cohort. Treatment discontinuation due to adverse events was 21.2% and 3.1%; study withdrawal due to adverse events in the registry was 4 and 1 participants.
- Hierarchical testing: under the treatment policy estimand, PROMIS-Fatigue (P = .059) did not reach significance, so formal testing ended before hypoxic burden, and the responder endpoint was not significant (P = .182).
- Patient-reported outcomes: the authors cite a placebo response in both arms and possible expectation bias, and state insomnia was not assessed in a standardized manner although the PAP-intolerant population may have been enriched for subclinical insomnia.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed. The editorial states the clinical significance of the placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study.
- Sponsor: the prospectus describes SynAIRgy as a trial the company conducted.